Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: The link between Parkinson's disease (PD), the second most common neurodegenerative disorder, and nonneuronopathic Gaucher disease (GD) is well established. Currently, PD is primarily associated with nonneuronopathic GD; however, with currently available treatments, patients with chronic neuronopathic GD, who historically had a shortened life span, are now living well into their 50s and beyond.
Cases: We highlight 4 patients with chronic neuronopathic GD with parkinsonian features, describing their GD genotype and phenotype as well as the presentation and progression of their parkinsonism. Symptoms presented in their fourth or fifth decade of life, and include unilateral bradykinesia and/or tremor. Of the patients, 3 had cognitive impairment. The fourth patient has not shown cognitive decline 6 years after PD onset.
Conclusion: This small series highlights that PD is not exclusively associated with nonneuronopathic GD and that as the chronic neuronopathic GD population ages, the clinical spectrum and heterogeneity of neurological manifestations may include parkinsonism.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7534005 | PMC |
| http://dx.doi.org/10.1002/mdc3.13031 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Analysis of fatal outcomes of patients with mucopolysaccharidosis type II according to the Russian mucopolysaccharidosis registry.
World J Clin Pediatr
September 2025
Hospital Pediatry, Saint-Petersburg State Pediatric Medical University, Saint-Petersburg 194100, Sankt-Peterburg, Russia.
Background: Mucopolysaccharidosis type II (MPS II) is a chronic inherited disease with multiorgan involvement, a progressive course, and restricted life expectancy.
Aim: To evaluate the predictors of fatal outcomes in MPS II patients.
Methods: In the retrospective cohort study, the clinical, laboratory data and enzyme replacement therapy (ERT) (84.
Gaucher disease type 3: Classification of the chronic neuronopathic variant informed by genotype in a phenotypically diverse cohort.
Genet Med
September 2025
University of Cambridge, Cambridge, United Kingdom.
Purpose: Type 3 Gaucher disease (GD), the chronic neuronopathic form caused by biallelic pathogenic variants in GBA1, is clinically heterogeneous, and there have been few comprehensive studies of its natural history and phenotypic diversity. The greatest unmet clinical need is for a disease-modifying treatment for the neurological manifestations; however, the inability to identify unifying features in the existing nomenclature that would facilitate establishment of eligibility criteria and suitable endpoints in clinical trials is a major challenge for therapeutic development.
Methods: A multicenter cohort study in England, GAUCHERITE, undertook retrospective and prospective clinical evaluation of patients with GD; this substudy is focused on patients with neuronopathic GD.
A novel mouse model of chronic neuronopathic Gaucher disease exhibits Parkinson's disease-like phenotypes.
Neurobiol Dis
June 2025
Key Laboratory of Metabolism and Molecular Medicine, Ministry of Education, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, 200032 Shanghai, China; Surgery laboratory, Institute of Medical Sciences, General Hospital of N
Gaucher disease (GD), the most common lysosomal storage disorder, is an autosomal recessive inherited disease caused by mutations in GBA1. It can be categorized into neuronopathic and non-neuronopathic types. We previously constructed mouse models carrying the Gba1 F213I point mutation and tamoxifen-inducible systemic Gba1 knockout mice, both of which developed disease rapidly and had a short lifespan.
View Article and Find Full Text PDFAcid sphingomyelinase deficiency: Laboratory diagnosis, genetic and epidemiologic aspects of a 50-year French cohort.
Mol Genet Metab
May 2025
Laboratoire Gillet-Mérieux, Hôpital Lyon-Sud, Hospices Civils de Lyon(1), and Centre de Biologie et de Pathologie Est, Hospices Civils de Lyon, Bron, France; Unité INSERM U820, Faculté de Médecine Lyon-Est, Lyon, France1. Electronic address:
Objectives: Laboratory diagnosis of acid sphingomyelinase (ASM) deficiency (ASMD) was implemented in France in the early 1970s. The aims of this study were (i) to review the combined use of successively developed strategies - enzyme measurement, genetic testing, and biomarkers analysis - and (ii) to describe the mutational spectrum and epidemiological characteristics of a large patient cohort followed in French hospitals.
Results: During the 1974-2023 period, 271 patients with ASMD (238 families) were diagnosed.